October 8, 2026Understand TRAVERSE prostate-event counts, PSA changes, exclusions, wide confidence intervals, monitoring, and current FDA labeling developments.- October 8, 2026Review randomized vaginal-estrogen UTI trials, episode rates, current guidance, and the differences between prevention, infection, and leakage.
- October 8, 2026Read SURMOUNT-1 blood-pressure results, 24-hour monitoring, confidence intervals, weight-loss mechanisms, and practical follow-up questions.
- October 8, 2026Explore MsFLASH estradiol and venlafaxine results, placebo response, safety questions, and realistic expectations for hot-flash treatment.
- October 8, 2026Explore SURMOUNT-5 weight and waist results, trial doses, safety limits, and how the head-to-head comparison differs from SURPASS-2.
- October 8, 2026Explore semaglutide appetite and meal studies, including 2026 findings on food thoughts, sustained intake changes, and nutrition considerations.
- October 8, 2026Read KEEPS and MsFLASH sleep results, distinguish questionnaire scores from sleep stages, and explore insomnia assessment and treatment questions.
- October 8, 2026Read sperm-suppression and recovery studies, understand fertility endpoints, and learn why contraceptive-trial timelines are not personal guarantees.
- October 8, 2026Explore human NR and NMN trials, including a 2026 comparison, and distinguish NAD+ biomarkers from insulin sensitivity, longevity, and product…
- October 8, 2026Compare T4DM and TRAVERSE: populations, glucose endpoints, hematocrit safety findings, and why TRT is not a stand-alone diabetes-prevention plan.
